Anti-CD38 mAb-based therapies have shown significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM), with robust improvements in PFS and OS across numerous studies [44,45,46,47]. The gene discussed is CD38; the disease is plasma cell myeloma.